| Literature DB >> 31396933 |
Abstract
T cells engineered to express chimeric antigen receptor (CAR) against the B cell antigen CD19 are achieving remarkable clinical effects on hematological malignancies. Allogeneic transplantation approach is promising for broaden application of CART therapy. iPSCs are one of the ideal cell sources for this approach. CAR-engineered iPSCs are demonstrated to give rise to CAR-engineered T cell and exert their effector function. In this section, we describe the method to generate CAR-engineered iPSCs and differentiate them into T cells.Entities:
Keywords: Chimeric antigen receptor; Immunotherapy; Induced pluripotent stem cells; Lentiviral transduction; T cell differentiation
Mesh：
Substances：
Year: 2019 PMID： 31396933 DOI： 10.1007/978-1-4939-9728-2_10
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745